[HTML][HTML] Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
E Bosco, L Hsueh, KW McConeghy… - BMC Medical Research …, 2021 - Springer
Background Major adverse cardiovascular events (MACE) are increasingly used as
composite outcomes in randomized controlled trials (RCTs) and observational studies …
composite outcomes in randomized controlled trials (RCTs) and observational studies …
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in …
HW Jung, CY Kim, SP Hong, HJ Bae… - The Journal of …, 2023 - Wiley Online Library
The authors performed this study to investigate the efficacy and safety of a rosuvastatin
(RSV)/amlodipine (AML) polypill compared with those of atorvastatin (ATV)/AML polypill. We …
(RSV)/amlodipine (AML) polypill compared with those of atorvastatin (ATV)/AML polypill. We …
Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia
CP Lin, TJ Hsu, YC Tung, FC Hsiao… - Journal of the …, 2024 - Am Heart Assoc
Background Hypertension and hypercholesterolemia are important risk factors for
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …
[HTML][HTML] The efficacy of rosuvastatin, amlodipine, and aspirin in the treatment of hypertension with coronary heart disease and its effect on platelet aggregation
J Fu, T Wang, B Li, N Zhao - Disease Markers, 2022 - hindawi.com
Objective. This study was to study the efficacy of rosuvastatin, amlodipine, and aspirin in the
treatment of hypertension with coronary heart disease and its effect on platelet aggregation …
treatment of hypertension with coronary heart disease and its effect on platelet aggregation …
[HTML][HTML] Beneficial effects of fixed-dose combination of amlodipine and atorvastatin in patients with concomitant hypertension and hypercholesterolemia: a multi …
CP Lin, FC Hsiao, CT Wu, YS Lin, SW Chen… - Acta Cardiologica …, 2022 - ncbi.nlm.nih.gov
Background Blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) are
important risk factors for cardiovascular (CV) diseases. Although treating these factors …
important risk factors for cardiovascular (CV) diseases. Although treating these factors …
[HTML][HTML] An experience on the model-based evaluation of pharmacokinetic drug-drug interaction for a long half-life drug
Y Hong, S Jeon, S Choi, S Han, M Park… - The Korean Journal of …, 2021 - ncbi.nlm.nih.gov
Fixed-dose combinations development requires pharmacokinetic drug-drug interaction
(DDI) studies between active ingredients. For some drugs, pharmacokinetic properties such …
(DDI) studies between active ingredients. For some drugs, pharmacokinetic properties such …
Perfil clínico e terapêutico anti-hipertensivo de pacientes ambulatoriais de um hospital público terciário do interior paulista: Antihypertensive clinical and therapeutic …
AV Santana, GHD Grande… - … Journal of Health …, 2022 - ojs.brazilianjournals.com.br
Introdução: A Hipertensão Arterial é uma das principais doenças que acometem a
população mundial sendo causada por um conjunto de fatores de risco. Nesse contexto, os …
população mundial sendo causada por um conjunto de fatores de risco. Nesse contexto, os …
[PDF][PDF] Pharmacokinetic and Pharmacodynamic Evaluation of a Sodium Bicarbonate Combination of Rabeprazole, a Proton-Pump Inhibitor, in Healthy Subjects
HJ Kim, S Jeong, MK Park, HY Kim, JH Lee, JG Hwang - 2022 - medtextpublications.com
Purpose: Proton-pump inhibitors, such as rabeprazole, are prone to degradation in stomach
acid. The use of Enteric-Coated (EC) forms minimizes this problem; however, these forms …
acid. The use of Enteric-Coated (EC) forms minimizes this problem; however, these forms …